nChroma Bio Cuts Workforce in Half, Ends Hepatitis B Trial
By Dr. Zubair Khalid, DVM, MS, PhD ·

Boston-based biotech nChroma Bio has laid off half of its employees and terminated a clinical trial of its lead hepatitis B virus (HBV) asset. The company called time on the experimental therapy, which was being developed as a potential cure for chronic HBV infection.
The layoffs mark the second round of workforce reductions at nChroma within the past 12 months. The latest cuts reduce the company’s headcount by 50 percent. nChroma has not disclosed how many employees remain after the reduction.
The terminated trial was the company’s most advanced program. nChroma had previously positioned the asset as a candidate for functional cure of hepatitis B. No details about the reasons for stopping the trial were provided in the announcement.
Chronic hepatitis B affects roughly 300 million people worldwide and is a leading cause of liver cirrhosis and cancer. Existing treatments can suppress the virus but rarely eliminate it, making functional cures a high-priority but difficult goal in drug development. Many companies have attempted to develop curative therapies, and clinical failures are common in this space. nChroma’s decision highlights the persistent challenges in achieving sustained viral clearance.
Source: original report